MAHLY
Medipal Holdings Corporation, a Tokyo-based Japanese company founded in 1898, primarily operates as a wholesaler of prescription pharmaceuticals throughout Japan. Beyond its core drug distribution, the company also sources and supplies a comprehensive range of healthcare-related products, including medical equipment, materials, and clinical diagnostic reagents, used from the earliest pre-symptomatic stages through treatment. Its services extend to offering post-marketing surveillance (PMS) to pharmaceutical manufacturers and investing in the development of orphan drugs. Medipal's extensive wholesale activities also encompass a diverse array of other goods, such as cosmetics, daily necessities, over-the-counter medications, and animal health products for companion animals. Furthermore, it provides raw materials for food processing in agriculture, fisheries, and livestock sectors, along with livestock feed additives, various seasonings, veterinary medical equipment, packaging materials, and industrial chemicals. In addition to its product distribution, Medipal delivers a suite of specialized services: conducting contract-based epidemiological and clinical studies, developing computerized medical supply and master product databases for healthcare facilities, and offering solutions for health insurance claims review, medical coding, outsourcing, and remote educational programs. Its operations further include managing life and non-life insurance agencies, providing cleaning services, overseeing distribution center logistics, offering commissioned delivery and staffing solutions, and developing and managing services for Class A health dispensing pharmacies. Medipal serves a broad client base, including hospitals, clinics, dispensing pharmacies, various retail outlets like drugstores, home centers, convenience stores, supermarkets, and discount stores, as well as animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company was previously known as Mediceo Paltac Holdings Co., Ltd. before adopting its current name in October 2009.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q4 | 25.56 | $922.3B | — |
| 2025 Q3 | 76.03 | $1.03T | — |
| 2025 Q2 | 62.00 | $969.0B | — |
| 2025 Q1 | 46.17 | $945.2B | $0 |
| 2025 Q4 | 19.43 | $864.2B | $0 |
| 2024 Q3 | 69.78 | $982.5B | $0 |
| 2024 Q2 | 61.05 | $915.4B | $0 |
| 2024 Q1 | 42.95 | $909.3B | $0 |